Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma

By sjmartinez • September 27, 2022

Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 Aug 19:S1558-7673(22)00174-4. doi: 10.1016/j.clgc.2022.08.006. Epub ahead of print. PMID: 36155169.

Tags: Bladder cancer, Checkpoint Inhibitor, Hematology/Oncology, immunotherapy, Outcomes, Platinum resistance, Publications

Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation

Hu R, Tran B, Li S, Stackpole ML, Zeng W, Zhou Y, Melehy A, Sadeghi S, Finn RS, Zhou XJ, Li W, Agopian VG. Noninvasive[...]

Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA

Vidula N, Blouch E, Hesler K, Niemierko A, Bardia A. Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA. Breast[...]

Bone Marrow Failure in Prostate Cancer: A Rare Case Initially Disguised as Thrombotic Thrombocytopenic Purpura

Dommaraju SR, Shodiya M, Henick K. Bone Marrow Failure in Prostate Cancer: A Rare Case Initially Disguised as Thrombotic Thrombocytopenic Purpura. Cureus. 2025 Mar 18;17(3):e80781.[...]